COVID-19 Update:

 

We assure the LEMS community that we have product available and anticipate no disruptions to our manufacturing facilities as they are all in the US and Canada.

For patients who wish to have more product on hand, please reach out to YourCatalystPathways.com to make sure that you can remain well supplied through this public health emergency.

Please follow @CatalystPharma on Facebook and Twitter for updates.

Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2

INDICATIONS AND USAGE: FIRDAPSE® is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS FIRDAPSE® is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS Seizures: FIRDAPSE® can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE® in patients who have a seizure while on treatment. FIRDAPSE® is contraindicated in patients with a history of seizures. Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE® should be discontinued and appropriate therapy initiated. ADVERSE REACTIONS The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms. To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

It's All About The Company You Keep

Catalyst Pharmaceuticals is committed to improving the lives of people with rare diseases

COVID-19 Update:

 

We assure the LEMS community that we have product available and anticipate no disruptions to our manufacturing facilities as they are all in the US and Canada.

For patients who wish to have more product on hand, please reach out to YourCatalystPathways.com to make sure that you can remain well supplied through this public health emergency.

Please follow @CatalystPharma on Facebook and Twitter for updates.

Now there’s an FDA-approved, first-line treatment for adults with LEMS.1,2

INDICATIONS AND USAGE: FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

FIRDAPSE is contraindicated in patients with:

  • A history of seizures
  • Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS

Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS

The most common adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

It's All About The Company You Keep

Catalyst Pharmaceuticals is committed to improving the lives of people with rare diseases

At Catalyst Pharmaceuticals, we understand that receiving a rare disease diagnosis can be extremely difficult. Often patients feel isolated and hopeless. That’s why we believe that, when you’re battling a rare disease—it’s all about the company you keep.

Our company is committed to developing novel, safe, and efficacious therapies that will improve the lives of people with rare and ultra-rare diseases.

Corporate Citizenship

 Social responsibility is at the heart of everything we do

 

 

.

A Singular Mission

To improve the lives of patients with rare and ultra-rare diseases

 

.

Partnering With Patients

Empowering patients to take an active role in their health care

 

.

Cutting-Edge Science

The innovation behind a breakthrough

 

 

.

Latest Press Releases